Curia Invests US$200 Million to Expand Facilities in the UK and USA
Introduction:
Curia is investing US$200 million to expand its sterile fill-finish facilities in Glasgow, UK, and Albuquerque, NM, USA.
Features:
The Glasgow expansion will introduce an integrated, isolator-based vial filling line and a new lyophilizer, more than doubling the current GMP batch size. The facility will support a broad range of drug products, including highly potent formulations.
The new capacity in Glasgow will allow batch sizes of up to 20,000 vials and feature robotic, lossless filling technology, increasing filling speeds fivefold.
Additionally, the Albuquerque site will benefit from two new isolated filling lines, adding over 70,000 square feet to its existing 200,000-square-foot manufacturing space. This will significantly increase Phase III clinical and commercial production capacity.
This new high-speed vial line, featuring automated freeze-drying, vial inspection, and packaging capabilities, is expected to be operational by Q3 2025.
The expansions in Glasgow and Albuquerque will strengthen the global sterile fill-finish network.
Specifications:
| Name | Curia |
| Type | US$ 200 million |
| Year | 2025 - 2026 |
